Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orantinib

Next Previous
Drug Profile

Orantinib

Alternative Names: SU 006668; SU 6668; TSU-68

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Taiho Pharmaceutical
  • Class Antineoplastics; Indoles; Propionic acids; Pyrroles; Small molecules
  • Mechanism of Action Fibroblast growth factor inhibitors; Platelet-derived growth factor inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer
  • Discontinued Solid tumours

Most Recent Events

  • 31 Jul 2014 Taiho Pharmaceutical terminates the phase III ORIENTAL trial for liver cancer (unresectable disease; combination therapy) in Japan, South Korea & Taiwan (NCT01465464)
  • 18 Feb 2014 Taiho Pharmaceutical completes enrolment in the phase III ORIENTAL trial for liver cancer (unresectable disease; combination therapy) in Japan, South Korea & Taiwan (NCT01465464)
  • 13 Apr 2012 Orantinib is still in phase I trials for Non-small cell lung cancer in Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top